- Coronary Stents Coronary Balloons Catheters Guide Wires Introducer Sheaths Accessories Peripheral Interventional Products
- Immunoassay Molecular Diagnostics Hematology Diagnostics POCT Lab Solution
- Structural Heart Diseases Products
- Vascular Access Blood Pressure Transducer Arterial Blood Sampler CVC Accessories IV Catheter Needle-free Connectors Insulin Injection Pain Relief
- Hemodialysis consumables Hemoperfusion Cartridge Dialysis machine
- ECG Patient Monitor Oximeter
- Cardiovasculars Oncology Anti-infectives Central Nervous System Others
- Endoscope Endoscopic Ultrasound System
- Trauma Implant Spinal Implant Artificial Joint Sports Medicine
- Pacemakers and Leads Equipments
- Metabolic Diseases Cardiovascular Diseases
- ELISA CLIA FIA
- Nucleic Acid Extraction Nucleic Acid Extraction ＆ PCR Kits Real-Time PCR
- Thrombelastography Analyzer Blood Grouping Platelet Aggregation
- POCT - FIA Colloidal Gold
- NeoECG Holter Monitor Portable ECG Monitor AI-ECG Pocket ECG
- Patient Monitor Vital Signs Monitor End-tidal Capnography
- Fingertip Oximeter Handheld Oximeter Wrist Oximeter Wearable Oximeter All-in-One Health Monitor POCT Solution
- OBS Locking Compression Plate Locking Plates Conventional Plates Mini Plates System Screws Patella Ring - Patented Product Metal Pins Cable System
- Internal Fixation System Laminoplasty Plate System Percutaneous Kyphoplasty Fusion Cage Cervical Fixation System
- Hip System Knee System
- Suture Anchor Suture Button
MWN110
Clinical Trials
View on ClinicalTrials.gov
Development Highlights
1. ActRIIA/B-Targeted Approach: MWN110 is an investigational antibody targeting ActRIIA/B signaling, a pathway involved in skeletal muscle and adipose tissue biology.
2. Body Composition as a Clinical Focus: Its Phase 1 study evaluates body weight alongside exploratory measures of muscle mass, body fat percentage, and visceral and subcutaneous fat.
3. Potential to Complement Incretin Therapy: Preclinical findings with semaglutide support further investigation of MWN110 in combination with GLP-1–based therapy to assess its effects on fat loss and muscle preservation.
For licensing and partnership inquiries, please contact us (bd@lepu-medical.com).
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
